CE3F4 NEW
| Price | $47 | $80 | $156 |
| Package | 5mg | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: CE3F4 | CAS No.: 143703-25-7 |
| Purity: 98.06% | Supply Ability: 10g |
| Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | CE3F4 |
| Description | CE3F4 is a selective antagonist of exchange protein directly activated by cAMP (Epac1; IC50s of 10.7 μM and 66 μM for Epac1 and Epac2(B), respectively). |
| In vitro | CE3F4 acts as a selective antagonist of the Epac1, demonstrating inhibitory concentrations (IC50) of 10.7 μM for Epac1 and 66 μM for Epac2(B), illustrating greater potency against Epac1 as compared to its (S)-stereoisomer ((S)-CE3F4, IC50, 56 μM), yet showing lesser activity than its (R)-stereoisomer ((R)-CE3F4, IC50, 5.8 μM). At a concentration of 20 μM, CE3F4 effectively inhibits Epac-induced Rap1 activation in HEK293 cells and significantly reduces the late-phase ERK activation prompted by glucose in INS-1 cells. Moreover, at 40 μM, it specifically targets Epac1's guanine nucleotide exchange activity without disturbing Rap1's function or the Epac1-Rap1 interaction. CE3F4 at a 50 μM concentration exhibits stronger inhibitory effects on the guanine nucleotide exchange factor (GEF) activity of Epac1 compared to both forms of Epac2. It also inhibits the Epac1 exchange activity induced by compound 007, with an IC50 of 23 ± 3 μM, while not affecting PKA activity. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.7 mM), Sonication is recommended. DMSO : 50 mg/mL (142.45 mM), Sonication is recommended. |
| Keywords | Inhibitor | inhibit | Epac2B | Epac1 | CE-3F4 | CE3F4 |
| Inhibitors Related | Adagrasib | BI-2493 | RMC-9805 | Bithionol | (R)-Naproxen | Ketoconazole | MRTX1133 | Sotorasib | RMC-7977 | Daraxonrasib | AMG410 | NMac1 |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Inhibitor Library | NO PAINS Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | GPCR Compound Library | Anti-Cancer Compound Library | MAPK Inhibitor Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $47.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-04-22 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY